<DOC>
	<DOCNO>NCT01026545</DOCNO>
	<brief_summary>This study randomize , investigator blind , subject blind , sponsor-open , placebo control , multiple dose escalating , sequential , parallel cohort study PF-04287881 . Subjects undergo screening procedure within 28 day prior dose . At least 1 day Screening visit , eligible subject meet entry criterion admit Clinical Research Unit ( CRU ) confine unit discharge Day 15 . Approximately 60 healthy volunteer ( 20 volunteer Japanese origin Cohorts 5 6 ) , 18 55 year age , male female ( woman non childbearing potential ) enrol randomized 4:1 ratio treatment either PF-04287881 placebo within cohort . Each cohort 10 day dose period consist 10 subject ( 8 active 2 placebo ) . In cohort , subject receive single daily oral dose either placebo PF-04287881 fast state 10 day .</brief_summary>
	<brief_title>Multiple Oral Dose Safety , Tolerability And Pharmacokinetic Study Of PF-04287881 In Healthy Adult Subjects</brief_title>
	<detailed_description>Following Serious Adverse Event ( potential Hy 's Law case ) , risk-benefit assessment review preliminary safety data , review Pfizer 's internal hepatic injury advisory panel , conclude PF-04287881 unacceptable therapeutic window . The FDA notify intention discontinue development 09April2010 .</detailed_description>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<criteria>Volunteers willing able confine Clinical Research Unit comply study schedule . Women nonchildbearing potential . Japanese subject must 4 Japanese grandparent born Japan . Previous antibiotic use within 14 day prior dose . Use antibiotics hospitalization within 90 day prior dose . History hypersensitivity macrolides ketolides . Presence clinically significant eye condition ( corrective lens ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>multiple-dose</keyword>
	<keyword>macrolide</keyword>
</DOC>